The Personalized Medicine Coalition issued a report today highlight the recent advances in precision medicine as well as the remaining challenges.
A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.
The group has detailed cost data, performed economic modeling, and provided cost estimation tools to help labs convey to payors the value of sequencing procedures.
A genetic testing utilization service launched by Stanford in 2015 helped cut the number of inappropriately ordered tests in half and saved about $250,000 during the first year.
Using whole-exome sequencing early in the diagnostic process could save $3,500 on average in patients who obtain a diagnosis from it and $1,700 in patients who do not.
The firms found that NGS-based carrier screening is more cost effective than genotyping-based testing for 14 disorders and results in fewer affected births.
The study found that Oncotype DX testing was associated with less frequent chemo use among women at a high clinical risk of recurrence and more frequent chemo in women considered low risk.
The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.
The NICE recommendation specifies the use of Oncotype DX for intermediate risk patients for whom doctors are unclear whether to prescribe chemotherapy.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.